Sensei Biotherapeutics FY 2023 net loss $34.1M; cash into Q4 2025; SNS-101 data due Q2 2024

Sensei Biotherapeutics, Inc.

2023-FY EPS reported -$1.22

Net loss $34.1M in FY2023 vs $48.6M in FY2022; R&D expense fell to $18.3M from $30.4M.
Cash, equivalents, and marketable securities $65.8M at Dec 31, 2023 (down from $107.1M); runway now into Q4 2025.
SNS-101 Phase 1/2: topline efficacy/biomarker data expected Q2 2024 (ahead of prior guidance); no DLTs in 33 patients.
Resource realignment: paused preclinical TMAb programs (SNS-102, SNS-103, SNS-201) to focus on SNS-101.
Appointed Ron Weitzman as part-time CMO (Jan 2024) and Stephanie Krebs as CBO (Nov 2023).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sensei Biotherapeutics, Inc. reported financial results for full year ended December 31, 2023.

Period: full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 28, 2024, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-049197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.